Name

BVCPP

Alternate names

BCVPP

Primary Site

None

Histology

None

Radiation

None

Remarks

None

Drugs for BVCPP

Name

Alternate Names

Ibenzmethyzin Hydrochloride
Matulane
Methylhydrazine
N-Methylhydrazine
Natulan
Natulane
Procarbazine hydrochloride
Ro-4-6467
Ro4-6467/1

Abbreviations

IBZ
MIH
PCB
PCH
PCI
PCZ

Category

Chemotherapy

Subcategory

Nonclassic alkylating agent

NSC Number

077213
77213

Primary Site

Brain tumors adjuvant and/or advanced disease
Cutaneous T-cell lymphoma
Hodgkin lymphoma
Non-Hodgkin lymphoma

Histology

None

Remarks

An orally administered hydrazine derivative antineoplastic agent. FDA approved in stages III, IV Hodgkin's lymphoma.

Coding

This drug should be coded

Name

Alternate Names

Alti-Prednisone
Alto-Pred
Ancortone
Apo-Prednisone
Colisone
Cortan
Dacortin
Delta-Dome#
Deltasone
Deltra
Fernisone Buffered
Keysone
Liquid Pred
Meticorten
Novo-Prednisone
Orasone
Panasol
Paracort#
Prednicen M
SK-Prednisone
Sterapred DS
Ultracorten
Winpred

Abbreviations

PDN
PRD
PRED

Category

Hormones and hormonal mechanisms

Subcategory

Glucocorticoid

NSC Number

10023
010023

Primary Site

Prednisone is used in regimens to treat multiple sites and histologies

Histology

None

Remarks

Code Prednisone when it is part of a drug regimen.

Do not code Prednisone when it is given to treat symptoms or as a single agent. In most cases when Prednisone is given by itself and not as part of a drug regimen, it does not affect the cancer and would not be coded as treatment.

Coding

Please see remarks for additional information

Name

Alternate Names

Asta B 518
B-518
Clafen Claphene
Cyclophosphamid
Cyclophosphan
Cyclophosphane
Cytophosphan
Cytoxan
Endoxan
Endoxana
Enduxan
Genoxal
Neosar
Procytox
Sendoxan
Tymtram
WR-138719

Abbreviations

CP
CPM
CTX
CTY
CYC
Cyclo
CYT
CYTOX
CYTX

Category

Chemotherapy

Subcategory

Alkylating agent

NSC Number

026271
26271

Primary Site

Breast
leukemia
lymphoma
multiple myeloma
neuroblastoma
ovarian cancer
retinoblastoma
soft tissue sarcoma
Wilm's tumor

Histology

None

Remarks

An effective antineoplastic agent and is used for a variety of cancers. FDA approved uses on breast cancer, ovarian carcinoma, leukemia, lymphomas, multiple myeloma, neuroblastma, retinoblastoma, soft tissue sarcoma, Wilm's tumor. Alkylating agent

Coding

This drug should be coded

Name

Alternate Names

29060-LE
Alkaban
LE-29060
Velban
Velbe
Velsar
Vinblastine
Vinblastine sulfate

Abbreviations

VBL
VELB
VLB

Category

Chemotherapy

Subcategory

Plant alkaloid

NSC Number

049842
49842

Primary Site

None

Histology

None

Remarks

A cell cycle specific chemotherapeutic agent; vinca plant alkaloid; mitotic inhibitor. FDA approved uses in 3rd line breast cancer, choriocarcinoma, palliative in stages III and IV Hodgkin's lymphoma, Kaposi's sarcoma, mycosis fungoides, palliative in non-Hodgkin's histiocytic/lymphocytic lymphoma, and advanced testicular carcinoma.

Coding

This drug should be coded

Name

Alternate Names

BiCNU
Carmustinea
DTI 015
DTI-015
DTI015
WR 139021
WR-139021
WR139021

Abbreviations

BCNU

Category

Chemotherapy

Subcategory

Alkylating agent

NSC Number

409962

Primary Site

Brain
Hodgkin Lymphoma
Kidney cancer
Multiple myeloma
Non-Hodgkin lymphoma

Histology

None

Remarks

Phase I FDA approved uses on brain tumor, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma. Guilford Pharmaceuticals.(nitrosourea) (alkylating agent)

Coding

This drug should be coded
Glossary